Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Earnings for Madrigal Pharmaceuticals, Inc. (MDGL)
Earnings in 2023 (TTM): $-373,630,000
According to Madrigal Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-373,630,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Madrigal Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-373,630,000 | $-373,630,000 |
| 2022 | $-295,350,000 | $-299,314,000 |
| 2021 | $-241,846,000 | $-241,078,000 |
| 2020 | $-202,244,000 | $-197,444,000 |
| 2019 | $-83,948,000 | $-72,812,000 |
| 2018 | $-32,811,000 | $-32,811,000 |
| 2017 | $-31,154,000 | $-31,154,000 |
| 2016 | $-26,388,000 | $-26,388,000 |
| 2015 | $-68,671,000 | $-68,671,000 |
| 2014 | $-86,161,000 | $-86,161,000 |
| 2013 | $-90,192,000 | $-90,192,000 |
| 2012 | $-62,790,000 | $-62,790,000 |
| 2011 | $-47,380,000 | $-47,380,000 |
| 2010 | $-37,467,000 | $-37,467,000 |
| 2009 | $79.09 M | $79.09 M |
| 2008 | $-92,618,000 | $-92,618,000 |
| 2007 | $-122,080,000 | $-63,495,000 |
| 2006 | $-59,129,000 | $-57,270,000 |
| 2005 | $-68,863,000 | $-68,863,000 |
| 2004 | $-47,517,000 | $-45,934,000 |
| 2003 | $-27,878,000 | $-27,878,000 |
| 2002 | $-54,352,000 | $-36,154,000 |
| 2001 | $ | $-381,000 |